Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients-Reference-Cited by-同舟云学术

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

Published:2015-02-15 Issue:1 Volume:19 Page:183-191
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Fuse Nozomu,Kuboki Yasutoshi,Kuwata Takeshi,Nishina Tomohiro,Kadowaki Shigenori,Shinozaki Eiji,Machida Nozomu,Yuki Satoshi,Ooki Akira,Kajiura Shinya,Kimura Tetsuo,Yamanaka Takeharu,Shitara Kohei,Nagatsuma Akiko Kawano,Yoshino Takayuki,Ochiai Atsushi,Ohtsu Atsushi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-015-0471-6.pdf

Reference37 articles.

1. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.

2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

3. Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9.

4. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9.

5. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15:1007–18.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review;World Journal of Gastrointestinal Oncology;2024-08-15

2. Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer;World Journal of Gastrointestinal Oncology;2024-06-15

3. Role of savolitinib in advanced gastric adenocarcinoma with meningeal carcinomatosis and cerebellar metastasis: A case report;World Journal of Clinical Cases;2024-05-26

4. Advances in MET tyrosine kinase inhibitors in gastric cancer;Cancer Biology & Medicine;2024-05-10

5. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance;The Oncologist;2024-05-06